CJC-1295 Dosing Protocol: Growth Hormone Research

Also known as: DAC:GRF

hormonal

Research Reference Only

This information is for educational purposes only. CJC-1295 is not FDA approved for human use. The protocols listed are summaries of published research studies and do not constitute medical advice. Always consult a licensed healthcare provider.

Overview

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) version extends its half-life. Research has examined its effects on growth hormone secretion.

Mechanisms of Action

Stimulates GH release from pituitary

Extended half-life with DAC

Increases IGF-1 levels

Pulsatile GH secretion pattern

Research Protocols

The following protocols are summaries of published research studies. They are presented for educational purposes only and do not constitute medical advice.

Protocol Name	Source	Dose	Frequency	Duration	Route	Evidence	Link
GH Secretion Study	clinical trial	30 μg/kg	Weekly	4 weeks	Subcutaneous	human

Important Warnings

Safety Considerations

Affects hormone levels
Requires medical supervision
Not approved for human use